A Randomized, Sham ‐Controlled Trial of Repetitive Transcranial Magnetic Stimulation Targeting M1 and S2 in Central Poststroke Pain: A Pilot Trial

ConclusionsS2 is a promising nrTMS target in the treatment of CPSP. TheDRD2 T/T genotype might be a biomarker for M1 nrTMS response, but this needs confirmation from a larger study.

https://onlinelibrary.wiley.com/doi/10.1111/ner.13496?af=R

Source: Neuromodulation: Technology at the Neural Interface - August 9, 2021 Category: Biotechnology Authors: Juhani Ojala, Jukka Vanhanen, Hanna Harno, Pantelis Lioumis, Selja Vaalto, Mari A. Kaunisto, Jukka Putaala, Marko Kangasniemi, Erika Kirveskari, Jyrki P. M äkelä, Eija Kalso Tags: Clinical Research Source Type: research